CCA
AMRX icon

Catalyst Capital Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Catalyst Capital Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-95,000
Closed -$458K – 233
2019
Q4 		$458K Buy
+95,000
New +$330K 0.01% 198

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Catalyst Capital Advisors's AMRX Position: Q1 2020 in Review

Catalyst Capital Advisors sold out of Amneal Pharmaceuticals (AMRX) in Q1 2020, closing a stake of 95,000 shares — an estimated $458K sold.

Catalyst Capital Advisors first reported a position in AMRX in Q4 2019 and held it in 1 quarter. The position peaked at $458K in Q4 2019. 127 funds tracked by Wall St. Rank hold AMRX as of Q1 2020.

  • Catalyst Capital Advisors reported no remaining Amneal Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Catalyst Capital Advisors sold 95,000 Amneal Pharmaceuticals shares in Q1 2020, an estimated $458K.
  • Catalyst Capital Advisors first reported a position in Amneal Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Catalyst Capital Advisors's Amneal Pharmaceuticals position peaked at $458K in Q4 2019.
  • 127 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2020.

Based on Catalyst Capital Advisors's 13F filing for Q1 2020, filed 12 May 2020.